Combination of a Ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells

Stem Cells

Volumn 29, Issue 4, 2011, Pages 590-599

  Hide, Takuichiro ^a,b   Takezaki, Tatsuya ^a,b   Nakatani, Yuka ^a   Nakamura, Hideo ^b   Kuratsu, Jun Ichi ^b   Kondo, Toru ^a,c  

^a RIKEN   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c EHIME UNIVERSITY   (Japan)

Author keywords

Glioma; Glioma initiating cells; HRas; Microarray; Neural stem cells; Oligodendrocyte precursor cells; p53

Indexed keywords

CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIREGULIN; GEFITINIB; HIGH MOBILITY GROUP A PROTEIN; MARKER; PROMININ1; PROSTAGLANDIN SYNTHASE; PROTEIN P53; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL LINEAGE; CELL TRANSFORMATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; ONCOGENE RAS; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FLOW CYTOMETRY; GENES, RAS; GLIOBLASTOMA; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; OLIGODENDROGLIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 79953773786     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.618     Document Type: Article

References (48)

1. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111. (Pubitemid 33041634)
2. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5:311-321. (Pubitemid 40488636)
3. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-833. (Pubitemid 350006257)
4. Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000;289:1754-1757.
5. Laywell ED, Rackic p, Kukekov VG et al. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci USA 2000;97:13889-13894.
6. Belachew S, Chittajallu R, Aguirre AA et al. Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. J Cell Biol 2003;161:169-186. (Pubitemid 36459089)
7. Nunes MC, Roy NS, Keyoung HM et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003;9:439-447. (Pubitemid 36460078)
8. Rasheed BK, McLendon RE, Herndon JE et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324-1330. (Pubitemid 24108076)
9. Bögler O, Huang HJ, Kleihues P et al. The p53 gene and its role in human brain tumors. Glia 1995;15:308-327.
10. Cancer Genome Atlas Research Network.Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
11. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812.
12. Jeuken J, van den Broecke C, Gijsen S et al. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 2007;114:121-133. (Pubitemid 47103523)
13. Reilly KM, Loisel DA, Bronson RT et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nature Genet 2000;26:109-113.
14. Zhu Y, Guignard F, Zhao D et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-130. (Pubitemid 41132741)
15. Tsukada T, Tomooka Y, Takai S et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 1993;8:3313-3322. (Pubitemid 23342629)
16. Kondo T, Raff M. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 2004;18:2963-2972. (Pubitemid 39602314)
17. Kondo T, Raff M. The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J 2000;19:1998-2007. (Pubitemid 30237575)
18. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-36. (Pubitemid 32095858)
19. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:article3.
20. Storey JD. A direct approach to false discovery rates. J R Stat Soc 2004;B64(part 3):479-498.
21. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-9445. (Pubitemid 37033947)
22. Johe KK, Hazel TG, Muller T et al. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 1996;10:3129-3140. (Pubitemid 27020541)
23. Rao MS, Noble M, Mayer-Pröschel M. A tripotential glial precursor cell is present in the developing spinal cord. Proc Natl Acad Sci USA 1998;95:3996-4001. (Pubitemid 28173242)
24. Wang S, Sdrulla A, Johnson JE et al. A role for the helix-loop-helix protein Id2 in the control of oligodendrocyte development. Neuron 2001;29:603-614. (Pubitemid 32323935)
25. Bizub D, Blair D, Alvord G et al. Correlation between H-ras p21TLeu61 protein content and tumorigenicity of NIH3T3 cells. Oncogene 1988;3:443-448. (Pubitemid 18265198)
26. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-229.
27. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828. (Pubitemid 37187480)
28. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
29. Uchida N, Buck DW, He D et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97:14720-14725. (Pubitemid 32016642)
30. Gasparini G, Longo R, Sarmiento R et al. Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol 2003;4: 605-615.
31. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors - The bull's-eye hits the arrow. Cancer Cell 2004;5:411-415. (Pubitemid 38610243)
32. Yuan X, Curtin J, Xiong Y et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23:9392-9400. (Pubitemid 40069671)
33. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-6970. (Pubitemid 37322983)
34. Torrance CJ, Jackson PE, Montgomery E et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-1028.
35. Zhang X, Chen ZG, Choe MS et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11:6261-6269. (Pubitemid 41262957)
36. Li L, Neaves WB. Normal stem cells and cancer stem cells: The niche matters. Cancer Res 2006;66:4553-4557.
37. Lyssiotis CA, Walker J, Wu C et al. Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc Natl Acad Sci USA 2007;104:14982-14987. (Pubitemid 47619579)
38. Chadee DN, Peltier CP, Davie JR. Histone H1(S)-3 phosphorylation in Ha-ras oncogene-transformed mouse fibroblasts. Oncogene 2002;21:8397-8403. (Pubitemid 36054882)
39. Dunn KL, He S, Wark L et al. Increased genomic instability and altered chromosomal protein phosphorylation timing in HRAS-transformed mouse fibroblasts. Genes Chromosomes Cancer 2009;48: 397-409.
40. He J, Kallin EM, Tsukada Y et al. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nat Struct Mol Biol 2008;15:1169-1175.
41. Agger K, Cloos PA, Rudkjaer L et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene-and stress-induced senescence. Genes Dev 2009;23:1171-1176.
42. Barradas M, Anderton E, Acosta JC et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 2009;23:1177-1182.
43. Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 2007;10:990-1002. (Pubitemid 47185206)
44. Ivkovic S, Canoll P, Goldman JE. Constitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matter. J Neurosci 2008;28:914-922. (Pubitemid 351159001)
45. Deininger MH, Meyermann R, Trautmann K et al. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression. Brain Res 2000;885:111-116.
46. Temel SG, Kahveci Z. Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J Mol Histol 2009;40:369-377.
47. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024. (Pubitemid 41609094)
48. Madhavan S, Zenklusen JC, Kotliarov Y et al. Rembrandt: Helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 2009;7:157-167.